189 related articles for article (PubMed ID: 14985144)
1. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.
Perloff MD; von Moltke LL; Greenblatt DJ
Xenobiotica; 2004 Feb; 34(2):133-50. PubMed ID: 14985144
[TBL] [Abstract][Full Text] [Related]
2. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.
Yokogawa K; Shimada T; Higashi Y; Itoh Y; Masue T; Ishizaki J; Asahi M; Miyamoto K
Biochem Pharmacol; 2002 Feb; 63(4):777-83. PubMed ID: 11992648
[TBL] [Abstract][Full Text] [Related]
3. Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.
Perloff MD; von Moltke LL; Cotreau MM; Greenblatt DJ
Biochem Pharmacol; 1999 Jun; 57(11):1227-32. PubMed ID: 10230766
[TBL] [Abstract][Full Text] [Related]
4. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative.
Luo G; Lin J; Fiske WD; Dai R; Yang TJ; Kim S; Sinz M; LeCluyse E; Solon E; Brennan JM; Benedek IH; Jolley S; Gilbert D; Wang L; Lee FW; Gan LS
Drug Metab Dispos; 2003 Sep; 31(9):1170-5. PubMed ID: 12920173
[TBL] [Abstract][Full Text] [Related]
5. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.
Salphati L; Benet LZ
Biochem Pharmacol; 1998 Feb; 55(4):387-95. PubMed ID: 9514072
[TBL] [Abstract][Full Text] [Related]
6. Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes.
Amacher DE; Schomaker SJ
Toxicol Lett; 1998 Jan; 94(2):115-25. PubMed ID: 9574808
[TBL] [Abstract][Full Text] [Related]
7. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
Weemhoff JL; von Moltke LL; Richert C; Hesse LM; Harmatz JS; Greenblatt DJ
J Pharm Pharmacol; 2003 Mar; 55(3):381-6. PubMed ID: 12724045
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
9. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level.
Cotreau MM; von Moltke LL; Beinfeld MC; Greenblatt DJ
J Pharmacol Toxicol Methods; 2000; 43(1):41-54. PubMed ID: 11091129
[TBL] [Abstract][Full Text] [Related]
10. Expression of cytochromes P450 3A in mouse lung: effects of dexamethasone and pregnenolone 16alpha-carbonitrile.
Haag M; Fautrel A; Guillouzo A; Frossard N; Pons F
Arch Toxicol; 2003 Mar; 77(3):145-9. PubMed ID: 12632254
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation by dexamethasone of fluvastatin-inducible CYP2B expression in primary cultures of rat hepatocytes: role of CYP3A.
Kocarek TA; Reddy AB
Biochem Pharmacol; 1998 May; 55(9):1435-43. PubMed ID: 10076536
[TBL] [Abstract][Full Text] [Related]
12. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
Matheny CJ; Ali RY; Yang X; Pollack GM
Drug Metab Dispos; 2004 Sep; 32(9):1008-14. PubMed ID: 15319343
[TBL] [Abstract][Full Text] [Related]
13. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
14. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
von Moltke LL; Durol AL; Duan SX; Greenblatt DJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):259-61. PubMed ID: 10952482
[TBL] [Abstract][Full Text] [Related]
15. Differential impairment of triazolam and zolpidem clearance by ritonavir.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
J Acquir Immune Defic Syndr; 2000 Jun; 24(2):129-36. PubMed ID: 10935688
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
[TBL] [Abstract][Full Text] [Related]
17. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .
Lin JH; Chiba M; Chen IW; Nishime JA; deLuna FA; Yamazaki M; Lin YJ
Drug Metab Dispos; 1999 Oct; 27(10):1187-93. PubMed ID: 10497146
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.
Perloff ES; Duan SX; Skolnik PR; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2005 Jun; 33(6):764-70. PubMed ID: 15764714
[TBL] [Abstract][Full Text] [Related]
19. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
